<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ENFUVIRTIDE</span><br/>(en-fu-vir'tide)<br/><span class="topboxtradename">Fuzeon<br/></span><b>Classifications:</b> <span class="classification">antiviral</span>; <span class="classification">antiretroviral</span>; <span class="classification">fusion inhibitor</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>90 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Enfuvirtide interferes with entry of HIV-1 into host cells by inhibiting fusion of the virus and cell membranes. For HIV-1
         to enter and infect a human cell, the viral surface glycoprotein gp120 must bind to the host CD4+ cell. Then, the viral glycoprotein
         gp41 undergoes a change in shape facilitating the fusion of viral membranes with the cell. Enfuvirtide binds to viral envelope
         glycoprotein and prevents the change in shape required for membrane fusion and viral entry into target cells.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Prevents entry of the HIV-1 virus into host cells.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of advanced HIV disease with evidence of resistance to other therapies.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to enfuvirtide or any of its components; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B); renal and hepatic impairment; renal clearance of 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Advanced HIV Disease</span><br/><span class="rdage">Adult/Adolescent:</span> <span class="rdroute">SC</span>
<i><img src="../images/special/greaterorequal.gif"/>16 y or <img src="../images/special/greaterorequal.gif"/>42.6 kg,</i> 90 mg b.i.d.<br/><span class="rdage">Child/Adolescent:</span> <span class="rdroute">SC</span>
<i>616 y or  2 mg/kg (up to 90 mg) b.i.d.<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Reconstitute by adding 1.1 mL sterile water for injection into vial. Mix by gently tapping vial for 10 sec, then gently rolling
            in palms of hands. Ensure that no drug is remaining on vial wall. Allow vial to stand until powder completely dissolves (up
            to 45 min). Solution should be clear, colorless, and without bubbles or particulate matter.
         </li>
<li>Bring refrigerated reconstituted solution to room temperature before injection. Ensure that powder is fully dissolved and
            solution is clear, colorless, and without bubbles or particulate matter.
         </li>
<li>Inject into upper arm, abdomen, or anterior thigh.</li>
<li>Rotate injection sites and inject in an area with no current injection site reaction.</li>
<li>Store unreconstituted vials at 15°30° C (59°86° F) or refrigerated at 2°6°
            C (3°46° F); do not freeze.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Injection site reactions (pain, induration, erythema, nodules, cysts, pruritus, ecchymoses),</span> infection at injection site, <span class="speceff-common">fatigue,</span> systemic hypersensitivity reactions, Guillain-Barré syndrome, asthenia, herpes simplex infections, influenza, lymphadenopathy,
      myalgia, peripheral neuropathy. <span class="typehead">CNS:</span> Anxiety, depression, <span class="speceff-common">insomnia.</span>
<span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea, nausea,</span> abdominal pain, anorexia, constipation, dysgeusia, pancreatitis, weight loss. <span class="typehead">Hematologic:</span> Eosinophilia, anemia. <span class="typehead">Metabolic:</span> Increased amylase, increased lipase, increased ALT and AST, hypertriglyceridemia. <span class="typehead">Respiratory:</span> Bacterial pneumonia, acute respiratory distress syndrome, cough, sinusitis. <span class="typehead">Skin:</span> Pruritus, skin papilloma. <span class="typehead"> Special Senses:</span>  Conjunctivitis. <span class="typehead">Urogenital:</span> Glomerulonephritis. 
      <h1><a name="interactions">Interactions</a></h1>None yet reported. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 84.3% absorbed from SC site. <span class="typehead">Peak:</span> Average 48 h. <span class="typehead">Distribution:</span> 92% protein bound. <span class="typehead">Metabolism:</span> Catabolized into constituent amino acids. <span class="typehead">Half-Life:</span> 4 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Inspect SC sites for S&amp;S of site reactions (e.g., itching, swelling, redness, pain, tenderness, or hardened skin) that usually
            last for 
         </li><li>Monitor closely for S&amp;S of pneumonia, especially with low initial CD4 count, high initial viral load, IV drug use, smoking,
            or prior history of lung disease.
         </li>
<li>Lab tests: Periodic LFTs, serum lipase and amylase, lipid profile, and CBC with differential.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly S&amp;S of infection at SC injection sites: increased heat, redness, pain, or oozing.</li>
<li>Report promptly S&amp;S of pneumonia: cough with fever, rapid breathing, shortness of breath.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>